What we know so far: COVID-19 current clinical knowledge and research

Melanoma vaccines: what we know so far.

Vaccines are a promising but still experimental treatment for melanoma. They are intended to stimulate immune responses against melanoma and by so doing, increase resistance against and slow the progression of this cancer. Key requirements for vaccines to be effective are that they contain antigens that can stimulate tumor-protective immune responses and that some of these antigens are present ...

The emotional attentional blink: what we know so far

The emotional attentional blink (EAB), also known as emotion-induced blindness, refers to a phenomenon in which the brief appearance of a task-irrelevant, emotionally arousing image captures attention to such an extent that individuals cannot detect target stimuli for several hundred ms after the emotional stimulus. The EAB allows for mental chronometry of stimulus-driven attention and the time...

Tracheal papillomatosis: what do we know so far?

Tracheal papillomatosis (TP) is a benign condition characterized by papillomatous growth of the bronchial epithelium that involves the trachea. This abnormal growth is a result of infection with human papilloma virus (HPV). Two subtypes of HPV were found in most cases of TP, HPV-6 and HPV-11. TP, presents in two forms, the juvenile onset (JO) or adult onset (AO). The clinical presentation is ty...

Mitochondrial cytopathy in adults: what we know so far.

Mitochondrial cytopathies are a diverse group of inherited and acquired disorders that result in inadequate energy production. They can be caused by inheritable genetic mutations, acquired somatic mutations, exposure to toxins (including some prescription medications), and the aging process itself. In addition, a number of well-described diseases can decrease mitochondrial energy production; th...

Coronavirus disease 2019 (COVID-19): What we need to know (In Press)